Medarex and Eli Lilly Collaborate on Therapeutic Antibody Development

Strategic Insights -

Medarex, Inc., a biopharmaceutical company, has agreed to produce fully human antibodies for several disease targets under a new collaboration with Eli Lilly and Company. This partnership will accelerate the introduction of antibody candidates into clinical investigation for important disease targets, leveraging Medarex's proprietary technologies and expertise. The agreement will provide Medarex with an immunization fee, license fees, milestone payments, and a royalty on sales of products arising from the partnership.

Key Takeaways:

  • Medarex will produce fully human antibodies for several disease targets under a new collaboration with Eli Lilly and Company.
  • The partnership will accelerate the introduction of antibody candidates into clinical investigation for important disease targets.
  • Medarex's HuMAb-Mouse(R) and TC Mouse(TM) systems will be used to create high-affinity, fully human antibodies.
  • The partnership will provide Medarex with an immunization fee, license fees, milestone payments, and a royalty on sales of products arising from the partnership.
  • Thomas F. Bumol, Ph.D., executive director, research technologies and proteins, at Lilly, stated that the agreement will benefit Lilly's expanding therapeutic antibody discovery program.
  • Donald L. Drakeman, president and CEO of Medarex, emphasized the significance of the partnership with a leading pharmaceutical company like Lilly.
  • Medarex has a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse(R), TC Mouse(TM), T-12 Development(SM), and Trans-Phage Technology(SM) systems.

Statistics:

  • Medarex has secured its 26th human antibody partnership with Eli Lilly and Company.
  • Lilly is developing a growing portfolio of best-in-class pharmaceutical products through collaborations with eminent scientific organizations.
  • Medarex provides a range of antibody development capabilities, including preclinical and clinical manufacturing services.

Sources:

  • Medarex web site at www.medarex.com
  • Eli Lilly and Company's investor relations department
  • Medarex's Annual Report on Form 10-K for the fiscal year ended December 31, 1999 (SEC filing)
  • Kirin Brewing Co., Ltd. (trademark owner of TC Mouse)